Obermatt
See Similar Stocks →

Annexon

NSQ:ANNX · US03589W1027
BiotechnologySmall

360° View

44
Price/Sales12
Price/Earnings48
Price/Book11
Dividend Yield—
Revenue Growth—
Profit Growth25
Capital Growth67
TSR 52w76
Leverage40
Liquidity73
Refinancing40
Combined34
Analyst Opinions26
Pro Holdings75
Opinion Changes80
Market Pulse77

Profile

CountryUSA
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeNASDAQGS
Founded2011
Employees114
Websiteannexonbio.com
ISINUS03589W1027
Last UpdateApr 2, 2026
Index & Theme
NephrologyNeurologyInflammationChronic DiseasesImmunologyOphthalmologyNeuroscienceCentral Nervous SystemRheumatologyBiotechnologyHealth CareHealth DiagnosticsLife ScienceTherapeutics

Description

Annexon, Inc. (‘Annexon’) operates as a biopharmaceutical company. The company is advancing the next generation platform of targeted immunotherapies aimed at complement-mediated neuroinflammatory diseases that impact nearly 10 million people worldwi…

Analysis

Annexon's 360° View rank of 44 places it below its peer average — better than 44% of its true peers.

It's growing solidly (66) and expensive versus peers (11). On safety it is financially sound (51), and the market shows favorable sentiment (69). Taken together, its Combined rank of 34 reads as below its peer average.

360° rank · history

1007550250
44
2026

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
12
—
—
—
Price/Earnings
48
—
—
—
Price/Book
11
—
—
—
Dividend Yield
—
—
—
—
Value (overall)
11
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Annexon with its peers
Candel Therapeutics
NMQ:CADL
52
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
ArriVent BioPharma
NMQ:AVBP
89
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Rocket Pharmaceuticals
NMQ:RCKT
31
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Castle Biosciences
NMQ:CSTL
10
CountryUSA
IndustryHealth Care Providers & Services
SizeMedium
Full Stock Analysis →
Gain Therapeutics
NMQ:GANX
59
CountryUSA
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →
Insmed
NSQ:INSM
51
CountryUSA
IndustryBiotechnology
SizeMedium
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →